Turbotodd

Ruminations on tech, the digital media, and some golf thrown in for good measure.

Archive for the ‘diabetes’ Category

JDRF and IBM Collaborate to Research Risk Factors for Type 1 Diabetes in Children

leave a comment »

IBM and JDRF, the leading global organization funding type 1 diabetes (T1D) research, today announced a new collaboration to develop and apply machine learning methods to analyze years of global T1D research data and identify factors leading to the onset of T1D in children.

T1D affects approximately 1.25 million Americans, and it currently does not have a cure. This research collaboration is expected to create an entry point for T1D in the field of precision medicine, by combining JDRF’s connections to research teams around the globe and its subject matter expertise in T1D research with the technical capability and computing power of IBM.

“At JDRF, we are absolutely committed to seeing a world without type 1 diabetes, and with this partnership, we’re adding some of the most advanced computing power in the world to our mission,” said Derek Rapp, JDRF President and CEO.

“JDRF supports researchers all over the world, but never before have we been able to analyze their data comprehensively, in a way that can tell us why some children who are at risk get T1D and others do not. IBM’s analysis of the existing data could open the door to understanding the risk factors of T1D in a whole new way, and to one day finding a way to prevent T1D altogether.”

IBM scientists will look across at least three different data sets and apply machine learning algorithms to help find patterns and factors at play, with the goal of identifying ways that could delay or prevent T1D in children. In order to match variables and data formats and compare the differing data sets, the scientists plan to leverage previously collected data from global research projects.

Data analysis will explore the inclusion of genetic, familial, autoantibody and other variables to create a foundational set of features that is common to all data sets. The models that will be produced will quantify the risk for T1D from the combined dataset using this foundational set of features. As a result, JDRF will be in a better position to identify top predictive risk factors for T1D, cluster patients based on top risk factors, and explore a number of data-driven models for predicting onset.

“Nearly 40,000 new cases of type 1 diabetes will be diagnosed in the U.S. this year. And each new patient creates new records and new data points that, if leveraged, could provide additional understanding of the disease,” says Jianying Hu, Senior Manager and Program Director, Center for Computational Health at IBM Research. “The deep expertise our team has in artificial intelligence applied to healthcare data makes us uniquely positioned to help JDRF unlock the insights hidden in this massive data set and advance the field of precision medicine towards the prevention and management of diabetes.”

Future phases of the collaboration may consist of furthering the analysis of big data toward the goal of better understanding causes of T1D. They may also consist of analyzing more complex datasets, such as microbiome and genomics or transcriptomics data. Finally, but no less importantly, the knowledge gained through these efforts could also help JDRF in its pursuit of a cure for people with T1D.

Written by turbotodd

August 18, 2017 at 10:39 am

Posted in diabetes, healthcare, ibm

Tagged with , , ,

IDx and IBM Watson Health Forge Alliance for Eye Health

with 2 comments

IBM Watson Health and IDx,LLC today announced a five-year strategic alliance to advance eye health through cognitive computing applications. 

The alliance aims to help primary care providers, hospitals, health systems, and integrated delivery networks deliver value-based care to patients with diabetic retinopathy and other serious eye conditions such as glaucoma and age-related macular degeneration. 

The alliance expands IBM Watson Health’s focus on eye health.

The alliance leverages more than a decade of IDx’s ophthalmic image analysis work and IBM’s cognitive healthcare offerings and global reach. As part of the alliance, IBM Watson Health has the option to distribute IDx offerings. Initially, IBM Watson Health intends to distribute IDx-DR — an automated solution for diabetic retinopathy screening currently available in the 31 countries that comprise the European Economic Area.

IBM Watson Health may expand its distribution of IDx-DR to Australia, Canada, and the United States upon regulatory approvals of the product.

There are 415 million adults with diabetes across the world today, with the number expected to grow by 50% to over 600 million by 2040. Each of these individuals is at high risk of developing diabetic retinopathy, which is one of the leading causes of preventable blindness in working age adults.

Most people that develop diabetic retinopathy have no symptoms until irreversible vision loss had occurred, making early disease detection critical to prevent blindness.

“Over the past decades, productivity in healthcare has not kept pace with other sectors.  Patients and providers worldwide are paying the price. Our mission at IDx has always been to transform the quality, accessibility, and affordability of global healthcare through the automation of medical screening to support physicians’ diagnoses. We are incredibly pleased to partner with IBM Watson Health, which shares this vision, and believe they will help us scale the IDx mission to its fullest potential,” said Dr. Michael Abramoff, Founder and President of IDx.

This announcement comes shortly after IBM announced that IDx joined the global IBM Watson medical imaging collaborative, which includes 24 members worldwide.

The collaborative has a working group on eye health which aims to accelerate Watson’s understanding of a range of high-impact diseases — such as glaucoma, age-related macular degeneration, and cardiovascular disease — using various imaging modalities including fundus and optical coherence tomography (OCT).

IDx-DR version 2.0 has CE marking as a Class IIa Medical Device for sale in the European Union. IDx products have not yet been cleared by the FDA and are not currently for sale in the United States. IDx is currently conducting a U.S.-based clinical trial of IDx-DR scheduled for completion this summer. 

Written by turbotodd

March 16, 2017 at 9:22 am

%d bloggers like this: